MX2016012104A - Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c. - Google Patents

Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.

Info

Publication number
MX2016012104A
MX2016012104A MX2016012104A MX2016012104A MX2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A
Authority
MX
Mexico
Prior art keywords
compounds
hepatitis
treatment
cyano containing
azabenzofuran
Prior art date
Application number
MX2016012104A
Other languages
English (en)
Inventor
F Kadow John
Wang Tao
J Eastman Kyle
Zhang Zhongxing
E Parcella Kyle
Yin Zhiwei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016012104A publication Critical patent/MX2016012104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I, que incluyen sus sales, además de composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (HCV) y pueden ser útiles en el tratamiento de los pacientes infectados con HCV. (ver Fórmula).
MX2016012104A 2014-03-21 2015-03-20 Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c. MX2016012104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968763P 2014-03-21 2014-03-21
PCT/US2015/021638 WO2015143255A1 (en) 2014-03-21 2015-03-20 Cyano containing azabenzofuran compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
MX2016012104A true MX2016012104A (es) 2016-12-09

Family

ID=52808191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012104A MX2016012104A (es) 2014-03-21 2015-03-20 Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.

Country Status (18)

Country Link
US (1) US9249152B2 (es)
EP (1) EP3119785B1 (es)
JP (1) JP2017509700A (es)
KR (1) KR20160126085A (es)
CN (1) CN106459070A (es)
AR (1) AR099820A1 (es)
AU (1) AU2015231139A1 (es)
CA (1) CA2943526A1 (es)
CL (1) CL2016002361A1 (es)
EA (1) EA201691777A1 (es)
ES (1) ES2688554T3 (es)
IL (1) IL247830A0 (es)
MX (1) MX2016012104A (es)
PE (1) PE20161224A1 (es)
SG (1) SG11201607750PA (es)
TW (1) TW201620914A (es)
WO (1) WO2015143255A1 (es)
ZA (1) ZA201606478B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119769A1 (en) * 2014-03-21 2017-01-25 Bristol-Myers Squibb Pharma Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
US9938273B2 (en) * 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009943B1 (ru) 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
AU2009214194B2 (en) 2008-02-14 2012-05-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5572725B2 (ja) * 2010-03-10 2014-08-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.

Also Published As

Publication number Publication date
PE20161224A1 (es) 2016-11-12
IL247830A0 (en) 2016-11-30
AU2015231139A1 (en) 2016-11-03
AR099820A1 (es) 2016-08-17
ZA201606478B (en) 2018-05-30
EP3119785A1 (en) 2017-01-25
SG11201607750PA (en) 2016-10-28
KR20160126085A (ko) 2016-11-01
EA201691777A1 (ru) 2016-12-30
JP2017509700A (ja) 2017-04-06
EP3119785B1 (en) 2018-08-15
TW201620914A (zh) 2016-06-16
US20150266886A1 (en) 2015-09-24
ES2688554T3 (es) 2018-11-05
CA2943526A1 (en) 2015-09-24
WO2015143255A1 (en) 2015-09-24
CL2016002361A1 (es) 2017-04-21
US9249152B2 (en) 2016-02-02
CN106459070A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
MX354958B (es) Metodos para el tratamiento de vhc.
NZ703064A (en) Inhibitors of hepatitis c virus
PH12015502230B1 (en) Novel viral replication inhibitors
MX2021004464A (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
EA201692550A1 (ru) Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
UY35390A (es) Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen
MX2016012104A (es) Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
TN2011000089A1 (en) Compounds for the treatment of hepatitis c
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
MY163245A (en) Hepatitis c virus inhibitors